Given the integrative regulatory role of MFAP4 in tumor immunity as well as ferroptosis, therapeutic regimens that block MFAP4 may be a promising strategy for the development of more comprehensive and specific tumor immunotherapy for gliomas. This evidence concerns the gene MFAP4 and neoplasm.